Navigation Links
Dow AgroSciences' Success Presented to Wall Street

Company Outlines Ambitious Growth Plans, Technology Leadership

INDIANAPOLIS, Feb. 12 /PRNewswire-FirstCall/ -- The growing technology share of Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), was the focus of a presentation made to investors earlier today by Jerome Peribere, president and CEO of Dow AgroSciences. Peribere was speaking at the Goldman Sachs Agricultural Chemicals Conference in New York City, where he reinforced Dow AgroSciences' technology-based strategy of growing its agricultural chemicals business while developing new biotechnology products and platforms.

"We believe the company with the best technology will ultimately generate the most value," said Peribere. "We are building our capabilities to do exactly that and provide our customers with revolutionary solutions."

He cited numerous examples of the Company's innovation -- from both the chemical and biological sides of the portfolio -- and highlighted the progress of the seeds business during 2007, including growth in the Americas for its corn, cotton, sunflower, and canola product portfolios.

A key move in 2007 was the Company's announcement of its SmartStax(TM) agreement with Monsanto, creating the industry's first eight-gene stack of traits in corn. As a result of this scientific breakthrough, Peribere expects Dow's HERCULEX(TM) insect protection technology to be on approximately 40 percent of U.S. corn acres in the SmartStax launch year of 2010 and on about 60 percent of acres by 2012. This technology package will be further enhanced when Dow AgroSciences launches its Dow Herbicide Tolerance technology in 2012 for corn, and in 2013 for cotton and soybeans.

Peribere concluded that growth for Dow AgroSciences will continue as the Company develops technology leadership, builds a billion-dollar corn business and advances its ag chemical pipeline.

About Dow

With annual sales of $54 billion and 46,000 employees worldwide, Dow is a diversified chemical company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. The Company delivers a broad range of products and services to customers in around 160 countries, connecting chemistry and innovation with the principles of sustainability to help provide everything from fresh water, food and pharmaceuticals to paints, packaging and personal care products. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted. More information about Dow can be found at

About Dow AgroSciences

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $3.8 billion. Learn more at

(TM)Trademark of Dow AgroSciences LLC

SmartStax(TM) is a trademark of Monsanto Company

SOURCE The Dow Chemical Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
5. Life on Mars pregnancy test successfully launched
6. Of mice and men: new male contraceptives successful in rodents and humans
7. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
8. AMDL to Present its China Success Story at Rodman & Renshaw 9th Annual Healthcare Conference
9. Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries
10. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
11. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
Post Your Comments:
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier ... models, has promoted Melanie Aregger to serve as Chief Operating Officer. , ... the management team and was promoted to Head of InSphero Diagnostics in ...
Breaking Biology Technology:
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
Breaking Biology News(10 mins):